-
公开(公告)号：US20240391908A1
公开(公告)日：2024-11-28
申请号：US18789977
申请日：2024-07-31
Applicant: Pfizer Inc.
Inventor： Andrew John Bessire , David James Edmonds , David Andrew Griffith , Amit Sumant Kalgutkar , Timothy Frank Ryder
IPC: C07D405/14 , A61K45/06 , C07D401/14
Abstract: The present invention provides compounds of Formula XA-1, XA-2, XA-3, XA-4, XA-5, or XA-6, or metabolites of Compound 1 or metabolites of a compound of Formula I, PA-I, or PA-III, including compositions and salts thereof, which are useful in the prevention and/or treatment of a disease or disorder such as T2DM, obesity, or NASH, as well as analytical methods related to the administration of Compound 1 or a compound of Formula I, PA-1, or PA-III.
-
公开(公告)号：US20210047325A1
公开(公告)日：2021-02-18
申请号：US17034295
申请日：2020-09-28
Applicant: Pfizer Inc.
Inventor： Mary Theresa Didiuk , Robert Lee Dow , David Andrew Griffith
IPC: C07D471/10 , C07D491/20 , C07D519/00 , A61K31/438 , A61K31/519 , A61K45/06 , C07D487/10 , A61K31/435
Abstract: The invention provides a compound of Formula (1) or a pharmaceutically acceptable salt of the compound, wherein R1, R2, R3, Z, A1, L and A2 are as described herein; pharmaceutical compositions thereof; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of an acetyl-CoA carboxylase enzyme(s) in an animal.
-
公开(公告)号：US09145416B2
公开(公告)日：2015-09-29
申请号：US14491016
申请日：2014-09-19
Applicant: Pfizer Inc.
Inventor： Mary Theresa Didiuk , Robert Lee Dow , David Andrew Griffith
IPC: A61K31/44 , C07D471/10 , C07D491/20 , C07D519/00 , A61K31/438 , A61K31/519 , A61K45/06 , C07D487/10 , A61K31/435
CPC classification number: C07D471/10 , A61K31/435 , A61K31/438 , A61K31/519 , A61K45/06 , C07D487/10 , C07D491/20 , C07D519/00
Abstract: The invention provides a compound of Formula (I) or a pharmaceutically acceptable salt of the compound, wherein R1, R2, R3, Z, A1, L and A2 are as described herein; pharmaceutical compositions thereof; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of an acetyl-CoA carboxylase enzyme(s) in an animal.
Abstract translation: 本发明提供式（I）化合物或其药学上可接受的盐，其中R1，R2，R3，Z，A1，L和A2如本文所述; 其药物组合物; 以及其用于治疗通过抑制动物体内的乙酰辅酶A羧化酶调节的疾病，病症或病症的用途。
-
公开(公告)号：US08507681B2
公开(公告)日：2013-08-13
申请号：US13644415
申请日：2012-10-04
Applicant: Pfizer Inc.
Inventor： Scott William Bagley , David Andrew Griffith , Daniel Wei-Shung Kung
IPC: C07D401/04 , C07D401/14 , A61K31/438
CPC classification number: C07D471/10 , C07D519/00
Abstract: The invention provides a compound of Formula (I) or a pharmaceutically acceptable salt of the compound, wherein R1, R2, R3 and R4 are as described herein; pharmaceutical compositions thereof; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of an acetyl-CoA carboxylase enzyme(s) in an animal.
-
公开(公告)号：US12065434B2
公开(公告)日：2024-08-20
申请号：US17546207
申请日：2021-12-09
Applicant: Pfizer Inc.
Inventor： Andrew John Bessire , David James Edmonds , David Andrew Griffith , Amit Sumant Kalgutkar , Timothy Frank Ryder
IPC: C07D405/14 , A61K45/06 , C07D401/14
CPC classification number: C07D405/14 , C07D401/14 , A61K45/06
Abstract: The present invention provides compounds of Formula XA-1, XA-2, XA-3, XA-4, XA-5, or XA-6, or metabolites of Compound 1 or metabolites of a compound of Formula I, PA-I, or PA-III, including compositions and salts thereof, which are useful in the prevention and/or treatment of a disease or disorder such as T2DM, obesity, or NASH, as well as analytical methods related to the administration of Compound 1 or a compound of Formula I, PA-1, or PA-III.
-
Patent Agency Ranking
公开(公告)号：US20220193063A1
公开(公告)日：2022-06-23
申请号：US17546228
申请日：2021-12-09
Applicant: Pfizer Inc.
IPC: A61K31/4545 , C07D405/14 , A61K31/506
Abstract: The present invention provides metabolites of Compound 1 or a compound of Formula I or III, including compositions and salts thereof, which are useful in the prevention and/or treatment of a disease or disorder such as T2DM, obesity, or NASH, as well as analytical methods related to the administration of Compound 1 or a compound of Formula I or III.
-
公开(公告)号：US11059833B2
公开(公告)日：2021-07-13
申请号：US17078257
申请日：2020-10-23
Applicant: Pfizer Inc.
Inventor： Samit Kumar Bhattacharya , Leanne Marie Buzon , Kevin James Filipski , David Andrew Griffith , Bethany Lyn Kormos , Luis Angel Martinez-Alsina , Russell Alan Miller , Matthew Richard Reese , Rachel Jane Roth Flach , Yuan Zhang
IPC: C07D495/04 , A61K31/155 , A61K31/4985 , A61K31/7048 , A61K45/06
Abstract: Described herein are compounds of Formula I, wherein R1, R2, and R3 are defined herein, their use as branched-chain alpha keto acid dehydrogenase kinase inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to treat, for example, diabetes, NASH and heart failure.
-
公开(公告)号：US10294225B2
公开(公告)日：2019-05-21
申请号：US15883109
申请日：2018-01-30
Applicant: PFIZER INC.
Inventor： Mary Didiuk , Robert Lee Dow , David Andrew Griffith
IPC: A61K31/44 , C07D471/10 , C07D491/20 , C07D519/00 , A61K31/438 , A61K31/519 , A61K45/06 , C07D487/10 , A61K31/435
Abstract: The invention provides a compound of Formula (I) or a pharmaceutically acceptable salt of the compound, wherein R1, R2, R3, Z, A1, L and A2 are as described herein; pharmaceutical compositions thereof; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of an acetyl-CoA carboxylase enzyme(s) in an animal.
-
19.发明申请公开(公告)号：US20160347752A1
公开(公告)日：2016-12-01
申请号：US15236635
申请日：2016-08-15
Applicant: PFIZER INC.
Inventor： Mary Didiuk , Robert Lee Dow , David Andrew Griffith
IPC: C07D471/10 , A61K31/435 , A61K45/06
CPC classification number: C07D471/10 , A61K31/435 , A61K31/438 , A61K31/519 , A61K45/06 , C07D487/10 , C07D491/20 , C07D519/00
Abstract: The invention provides a compound of Formula (I) or a pharmaceutically acceptable salt of the compound, wherein R1, R2, R3, Z, A1, L and A2 are as described herein; pharmaceutical compositions thereof; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of an acetyl-CoA carboxylase enzyme(s) in an animal.
Abstract translation: 或其药学上可接受的盐，其中R1，R2，R3，Z，A1，L和A2如本文所述; 其药物组合物; 以及其用于治疗通过抑制动物体内的乙酰辅酶A羧化酶调节的疾病，病症或病症的用途。
-
20.发明申请公开(公告)号：US20150011470A1
公开(公告)日：2015-01-08
申请号：US14491016
申请日：2014-09-19
Applicant: Pfizer Inc.
Inventor： Mary Theresa Didiuk , Robert Lee Dow , David Andrew Griffith
IPC: C07D471/10 , A61K45/06 , A61K31/519 , A61K31/435
CPC classification number: C07D471/10 , A61K31/435 , A61K31/438 , A61K31/519 , A61K45/06 , C07D487/10 , C07D491/20 , C07D519/00
Abstract: The invention provides a compound of Formula (I) or a pharmaceutically acceptable salt of the compound, wherein R1, R2, R3, Z, A1, L and A2 are as described herein; pharmaceutical compositions thereof; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of an acetyl-CoA carboxylase enzyme(s) in an animal.
Abstract translation: 本发明提供式（I）化合物或其药学上可接受的盐，其中R1，R2，R3，Z，A1，L和A2如本文所述; 其药物组合物; 以及其用于治疗通过抑制动物体内的乙酰辅酶A羧化酶调节的疾病，病症或病症的用途。
-
-
-
-
-
-
-
-
-
Search Results
31
records
(took 0.03 seconds)
